Oventus Medical Ltd (ASX:OVN)'s John Cox provides an overview of the company's mission after its interim financial results were released on Monday. The dental services organisation and medtech stock is developing solutions to help manage sleep-disordered breathing — technology that could rival the industry-standard CPAP machine. Looking at financials, Oventus booked $544,000 in revenue over FY22's first half following its best-on-record second quarter.
Oventus Medical out to transform the sleep-disordered breathing market with new tech
